House Bill 567 would require broader coverage of biomarker testing in North Carolina health insurance and Medicaid. The bill defines biomarker testing broadly to include analysis of tissue, blood, or other biospecimens for biomarkers, including gene mutations, protein expression, and advanced sequencing tests. It requires health benefit plans to cover biomarker testing when supported by medical and scientific evidence, and it lists several sources that qualify as support, including FDA labeling, Medicare coverage determinations, and nationally recognized clinical practice guidelines and consensus statements.
The bill also amends existing insurance law to prohibit insurers from using genetic or biomarker information to raise group premiums, deny coverage, or charge higher rates for health benefit plans. It extends the new biomarker-testing coverage requirement to the State Health Plan and directs the Department of Health and Human Services to ensure Medicaid coverage for biomarker testing to the same extent required for private health benefit plans. The bill takes effect in stages, with most insurance-related provisions effective October 1, 2025, and the State Health Plan changes applying at the start of the next plan year after that date.
HB567 would amend Chapter 58 of the General Statutes to create a new coverage mandate for biomarker testing and revise existing protections related to genetic and biomarker information in health insurance. It would also incorporate that coverage mandate into the State Health Plan under Chapter 135 and require DHHS to align Medicaid laboratory services coverage policies with the new standard. In practical terms, insurers, the State Health Plan, and Medicaid would need to cover biomarker testing for diagnosis, treatment, care management, or monitoring when supported by specified clinical evidence, while insurers would remain barred from using biomarker or genetic information in underwriting decisions.
The available record shows no committee transcript or recorded votes, so there is no direct evidence of floor debate or partisan division in the materials provided. Based on the bill text, the measure is framed as a patient-access and diagnostic-improvement bill, suggesting a generally supportive policy rationale centered on earlier and more accurate diagnosis, especially for dementia and related conditions. The committee substitute favorable status also suggests the bill advanced in committee without visible opposition in the provided record.
The main policy questions likely concern the scope and cost of the coverage mandate, including how broadly biomarker testing is defined, what counts as sufficient medical and scientific evidence, and how insurers and public programs will absorb the added coverage obligations. Another possible point of contention is the bill’s reliance on external standards such as FDA labeling, Medicare determinations, and clinical guidelines, which may raise concerns about administrative complexity or future changes in coverage criteria. No specific opponents or amendments are identified in the provided materials.